Study of MRG007 for advanced solid tumors
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a new drug called MRG007 for people with advanced solid tumors that haven't responded to other treatments. The drug targets a protein called CDH17 on cancer cells; you need a tumor sample to check for it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be willing to sign an informed consent form and follow the study plan.
- Your doctor expects you to live at least 3 more months.
- You need a tumor sample to test for CDH17, or you must be willing to have a biopsy to get one.
- You must have advanced or metastatic cancer that has not responded to standard treatments, you couldn't tolerate them, or there are no standard options left.
- You need to have at least one tumor that can be measured on a scan.
- Your daily activity level must be fairly good (able to take care of yourself and do light work).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called MGC026 that targets a protein called B7-H3 on cancer cells, aiming to shrink or slow different advanced solid tumors. It is an early-phase study to find the right dose and check safety.
This trial tests a new drug called DM002 for people with advanced solid tumors that have not responded to standard treatments. The drug targets two proteins (MUC1 and HER3) found on some cancer cells, and may help shrink tumors or slow their growth.
This trial tests a new drug called BG-C137 for people with advanced solid tumors that have stopped responding to other treatments. The drug targets a protein called FGFR2b found on some cancer cells, aiming to deliver a therapy directly to the tumor.
This trial tests a new drug called MRG007 combined with other treatments for people with advanced colorectal cancer that cannot be removed by surgery or has spread. It aims to see if the combination is safe and effective.
This trial tests a new drug, MRG006A, for people with advanced solid tumors, especially liver cancer. It aims to see if the drug is safe and effective by targeting a protein called GPC3 found on some cancer cells.
This trial tests a new drug combination called MRG006A for people with advanced liver cancer (hepatocellular carcinoma) that cannot be removed by surgery or treated with local therapies. The goal is to see if it helps shrink tumors or slow cancer growth.
Hear when a new Locally Advanced or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.